HCPLive Podcasts

HCPLive.com
  • 5.0 (4)
  • Medicine
  • Updated Daily

Your destination feed for medical, health care and clinical science podcasts courtesy of HCPLive—featuring our shows Medical Ethics Unpacked, New Insight, and 5 Stories in Under 5.

  1. Joint Ventures: EULAR 2026 Congress Preview

    May 29

    Joint Ventures: EULAR 2026 Congress Preview

    In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, preview their unofficial countdown of the sessions, themes, and abstracts they are most excited about heading into the 2026 European Alliance of Associations for Rheumatology (EULAR) Annual Meeting in London, June 3–6, including:  Obesity, Weight Management, and Psoriatic Arthritis Sessions Personalized Medicine and Biomarkers in RMDs Sessions Fatigue and Quality of Life in Connective Tissue Disease Session Mitochondrial DNA and Interferon: Upstream Drivers of Autoimmunity Session Artificial Intelligence and Pattern Recognition in Rheumatology Sessions Axial Imaging in Axial Spondyloarthritis Session Head-to-Head Superiority Trials in RA and PsA Sessions CAR-T and CAR-NK Therapies: Efficacy, Limits, and What Comes Next Sessions

    43 min
  2. Joint Ventures: The B-Cell Story, Part 2 — Ianalumab and the Next Chapter in Sjögren's and Lupus

    May 28

    Joint Ventures: The B-Cell Story, Part 2 — Ianalumab and the Next Chapter in Sjögren's and Lupus

    In the second part of this Joint Ventures episode on B cell therapies in rheumatic disease, hosts Jack Arnold, MBBS, PhD, and Rihards Buss, MD, return with guest Lucy Carter, MBBS, PhD, to move beyond the question of how to deplete B cells and toward the more conceptually challenging problem of what happens after depletion — and whether ianalumab's dual mechanism of action represents the most rational answer yet developed. The episode examines the biologic rationale behind combining rituximab with belimumab, reviews the landmark NEPTUNUS Sjögren disease trials in which ianalumab became the first targeted therapy to meet a phase 3 primary endpoint in the disease, and discusses how emerging therapies may ultimately reshape treatment selection, steroid reduction strategies, and long-term management of autoimmune conditions including Sjögren disease and systemic lupus erythematosus.

    36 min
  3. Joint Ventures: The B-Cell Story, Part 1 — From Rituximab to the Next Frontier

    May 28

    Joint Ventures: The B-Cell Story, Part 1 — From Rituximab to the Next Frontier

    In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, are joined by guest Lucy Carter, MBBS, PhD, a consultant rheumatologist at Newcastle upon Tyne NHS Foundation Trust and honorary clinical senior lecturer at Newcastle University, to examine nearly 2 decades of B cell–targeted therapy in rheumatic disease — a story that has proven considerably more complicated than its early promise suggested. Carter, Arnold, and Buss trace the mixed legacy of rituximab in lupus and Sjögren disease and examining how incomplete B cell depletion, BAFF-driven rebound, and trial design limitations may have contributed to disappointing early results. The discussion then turns to newer approaches such as obinutuzumab, whose positive REGENCY and ALLEGORY trial data in lupus nephritis and systemic lupus erythematosus suggest that deeper, more durable B cell depletion may improve outcomes, while emerging CAR-T data raise broader questions about the future role of intensive immune reprogramming in autoimmune disease.

    30 min
  4. Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 2

    May 28

    Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 2

    In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, turn from osteoarthritis to the inflammatory arthritides — examining what early data in rheumatoid arthritis (RA), psoriatic arthritis (PsA), and lupus can and cannot yet tell us about the role of GLP-1 receptor agonists in disease modification. “Everyone is talking about [GLP-1 RAs] and what it can do for our patients. Much more evidence is needed to be much more better understanding about increasing effects beyond weight loss is needed. And I think that evidence will be just coming out very rapidly, year by year… but I think this is not the case where we're going to wait for strong evidence, good quality RCT data before we start to start to use them,” Buss said.

    28 min
  5. Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 1

    May 28

    Joint Ventures: GLP-1 Receptor Agonists — From Metabolic Drug to Immunomodulator? Part 1

    In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MD, a consultant rheumatologist at Freeman Hospital, Newcastle, examine the growing evidence for GLP-1 receptor agonists in rheumatological disease — drugs originally developed for glycemic control that are now drawing serious attention as potential immunomodulators with implications across the specialty. The conversation opens by tracing the arc of GLP-1 agonist development, from exenatide's approval in 2005 through to semaglutide's landmark cardiovascular and renal data in the SELECT1 and FLOW2 trials, before turning to the question now quietly circulating in rheumatology clinics: are these drugs doing something beyond shifting weight?

    29 min
  6. Joint Ventures: Nipocalimab Advances and a Deucravacitinib Decision Looms

    May 28

    Joint Ventures: Nipocalimab Advances and a Deucravacitinib Decision Looms

    In this episode of Joint Ventures, hosts Jack Arnold, MBBS, PhD, an academic clinical lecturer in rheumatology at the University of Leeds, and Rihards Buss, MBBS, a consultant rheumatologist at Freeman Hospital, dive into 2 emerging therapeutic strategies with the potential to reshape care for systemic lupus erythematosus (SLE) and psoriatic arthritis (PsA): Fc receptor blockade with nipocalimab and tyrosine kinase 2 (TYK2) inhibition with deucravacitinib, distinct pathways united by a shared goal of greater precision in immune modulation.

    25 min
  7. Introducing Joint Ventures, With Jack Arnold, MBBS, PhD, and Rihards Buss, MBBS

    May 28

    Introducing Joint Ventures, With Jack Arnold, MBBS, PhD, and Rihards Buss, MBBS

    Introducing Joint Ventures — a new podcast exploring advances in rheumatologic disease and what they mean for real-world practice. Hosted by RheumatologyLive, the series is led by Jack Arnold, MBBS, PhD, and Rihards Buss, MBBS, 2 United Kingdom-based rheumatologists united by a shared interest in translating rapidly evolving science into thoughtful, patient-centered care. Joint Ventures is designed for rheumatologists and clinicians managing immune-mediated disease who are navigating an increasingly complex therapeutic landscape. Each episode will examine emerging evidence, new mechanisms of action, and shifting paradigms in rheumatology, with a focus on how these developments intersect with clinical reasoning, uncertainty, and long-term patient management. Arnold is an academic clinical lecturer in rheumatology at the Leeds Institute of Rheumatic and Musculoskeletal Medicine in University of Leeds, with research interests spanning systemic lupus erythematosus, clinical trials, and the application of deep learning in medicine. Buss is a consultant rheumatologist specializing in psoriatic arthritis at Newcastle’s Freeman Hospital, with a particular focus on integrating new data into day-to-day clinical decision-making.

    23 min
  8. Closing the Gap Between IBD Therapies and Patient Outcomes, With David Rubin, MD

    May 6

    Closing the Gap Between IBD Therapies and Patient Outcomes, With David Rubin, MD

    Despite more than 14 approved therapies for Crohn's disease and ulcerative colitis, many patients still aren't reaching remission. At DDW 2026, David Rubin, MD, of the University of Chicago Medicine explains why the problem isn't the drugs — it's how and when we use them. He covers early treatment strategies, treat-to-target monitoring, the induction pitfall, and when to switch mechanisms rather than cycling within class. Read more: https://www.hcplive.com/view/closing-the-gap-between-ibd-therapies-and-patient-outcomes-with-david-rubin-md

    11 min
See All (243)

Ratings & Reviews

5
out of 5
4 Ratings

About

Your destination feed for medical, health care and clinical science podcasts courtesy of HCPLive—featuring our shows Medical Ethics Unpacked, New Insight, and 5 Stories in Under 5.

Information

  • Creator
    HCPLive.com
  • Years Active
    2019 - 2026
  • Episodes
    243
  • Rating
    Clean
  • Show Website
    HCPLive Podcasts